NCT05999825Unknown2 期
Safety and Preliminary Efficacy of Sm-p80 + GLA-SE (SchistoShield®) Vaccine Against Controlled Human Schistosome Infection in Healthy, Schistosoma-naïve Adults
Leiden University Medical Center0 个研究点目标入组 48 人开始时间: 2024年9月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 48
- 主要终点
- Vaccine efficacy
研究概览
简要总结
The goal of this clinical trial is to learn about the Sm-p80 + GLA-SE (Schistoshield®) vaccine in healthy participants who have not had schistosomiasis before. The main questions it aims to answer are:
- if the vaccine is safe
- if after vaccinated people start producing antibodies
- if the vaccine works against schistosomiasis.
Participants will receive three vaccines (or placebo) and are then exposed to 20 male Schistosoma cercariae. Afterwards they are treated with praziquantel to cure the infection.
Researchers will compare the group vaccinated with Schistoshield® and placebo (fake vaccination) to see if the vaccine has worked.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject is aged ≥ 18 and ≤ 45 years and in good health.
- •Subject has adequate understanding of the procedures of the study and agrees to abide strictly thereby.
- •Subject is able to communicate well with the investigator, is available to attend all study visits.
- •Subject will not travel to Schistosoma-endemic countries up until treatment at week
- •Subject agrees to refrain from blood and plasma donation to Sanquin or for other purposes throughout the study period.
- •For female subjects: subject agrees to use adequate contraception and not to breastfeed for the duration of study.
- •Subject has signed informed consent.
排除标准
- •Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immune-deficient, (severe) psychiatric and other disorders, which could compromise the health of the participant during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following:
- •body weight <50 kg or Body Mass Index (BMI) <18.0 or >35.0 kg/m2 at screening;
- •positive HIV, HBV or HCV screening tests;
- •the use of immune modifying drugs within three months prior to study onset (inhaled and topical corticosteroids and oral anti-histamines exempted) or expected use of such during the study period;
- •history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years;
- •any history of treatment for severe psychiatric disease by a psychiatrist in the past year;
- •history of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset.
- •The chronic use of any drug known to interact with praziquantel, artesunate or lumefantrine metabolism (e.g. phenytoïn, carbamazepine, phenobarbital, primidon, dexamethason, rifampicine, cimetidine, flecaïnide, metoprolol, imipramine, amitriptyline, clomipramine, class IA and III anti-arrythmics, antipsychotics, antidepressants, macrolides, fluorchinolones, imidazole- and triazole antimycotics, antihistamines). Because lumefantrine may cause extension of QT-time, chronic use of drugs with effect on QT interval will result in exclusion from study participation.
- •Any planned vaccination within 28 days before the start of the trial until the end of the immunisation phase (week 12), with the exception of SARS-CoV-2 vaccines or influenza vaccines.
- •For female subjects: positive serum pregnancy test on the day before first immunisation.
- •Any history of schistosomiasis or treatment for schistosomiasis.
- •Positive serology for schistosomiasis or elevated serum CAA at screening.
- •Known hypersensitivity to or contra-indications (including co-medication) for use of praziquantel, artesunate or lumefantrine.
- •Being an employee or student of the department of Parasitology or Infectious diseases of the LUMC.
结局指标
主要结局
Vaccine efficacy
时间窗: week 12-24, i.e. after challenge
The protective efficacy of Sm-p80 + GLA-SE to male Sm cercariae measured by the difference in frequency of serum CAA positivity (≥1.0 pg/mL) between the vaccine group and placebo
次要结局
- Safety of (repeated) immunisation(week 0-12)
- Immunogenicity(week 0-24)
研究者
Meta Roestenberg
Prof.
Leiden University Medical Center
相似试验
已完成
2 期
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DoseHaemophilus Influenzae Type bPoliomyelitisAcellular PertussisDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria MeniHepatitis BDiphtheriaTetanusNCT01171989GlaxoSmithKline391
已完成
2 期
Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of AgeHaemophilus Influenzae Type bPoliomyelitisAcellular PertussisDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria MeniDiphtheriaHepatitis BTetanusNCT00970307GlaxoSmithKline421
已完成
2 期
Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in ChildrenInfluenzaNCT01323946GlaxoSmithKline113
已完成
3 期
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and ChildrenInfluenzaNCT02207413GlaxoSmithKline1,886
已完成
3 期
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and OlderInfluenzaNCT01440387GlaxoSmithKline112